Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

PLASMIDS AND PHAGES FOR HOMOLOGOUS RECOMBINATION AND METHODS OF USE

  • Read more about PLASMIDS AND PHAGES FOR HOMOLOGOUS RECOMBINATION AND METHODS OF USE
US Patent 7,674,621
Filed on 2005-05-20

Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use

  • Read more about Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use
Patent Cooperation Treaty
PCT/US2005/018778
Filed on 2005-05-27

GENE-CASSETTE FOR ENHANCEMENT OF PROTEIN PRODUCTION

  • Read more about GENE-CASSETTE FOR ENHANCEMENT OF PROTEIN PRODUCTION
Patent Cooperation Treaty
PCT/US2005/17001
Filed on 2005-05-17

Recombinant Immunotoxin and Use in Treating Tumors

  • Read more about Recombinant Immunotoxin and Use in Treating Tumors
Canada
2508519
Filed on 2003-12-01

Recombinant Immunotoxin and Use in Treating Tumors

  • Read more about Recombinant Immunotoxin and Use in Treating Tumors
Australia
2003298794
Filed on 2003-12-01

Recombinant Immunotoxin And Use in Treating Tumors

  • Read more about Recombinant Immunotoxin And Use in Treating Tumors
US Application 10/537,061
Filed on 2005-06-01

Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2

  • Read more about Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2
Canada
2506684
Filed on 2003-11-19

Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2

  • Read more about Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2
Australia
2003298677
Filed on 2003-11-19

Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2

  • Read more about Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2
European Patent
03796431.9
Filed on 2003-11-19

IMMUNOTOXIN CONTAINING A DISULFIDE-STABILIZED ANTIBODY FRAGMENT JOINED TO A PSEUDOMONAS EXOTOXIN THAT DOES NOT REQUIRE PROTEOLYTIC...

  • Read more about IMMUNOTOXIN CONTAINING A DISULFIDE-STABILIZED ANTIBODY FRAGMENT JOINED TO A PSEUDOMONAS EXOTOXIN THAT DOES NOT REQUIRE PROTEOLYTIC...
United Kingdom
96934165.0
Filed on 1996-10-11

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 1037
  • Page 1038
  • Page 1039
  • Page 1040
  • Page 1041
  • Page 1042
  • Page 1043
  • Page 1044
  • Page 1045
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health